Pfizer licenses Starna Therapeutics' in vivo CAR-T programmes in deal worth up to $2.63 billion

Pfizer has secured rights to three preclinical in vivo CAR-T programmes from Starna Therapeutics through a licensing agreement featuring $330 million upfront and up to $2.3 billion in contingent milestone payments.
Pfizer announced on 18 November 2026 that it had entered into an exclusive licensing agreement with Starna Therapeutics covering three preclinical in vivo CAR-T programmes targeting autoimmune diseases, alongside broader technology rights spanning immunology and oncology.
The agreement provides Starna with $330 million upfront and eligibility for up to $2.3 billion in development and commercial milestones plus royalties, with Pfizer leading clinical development outside Greater China; the approximately $2.63 billion maximum potential consideration excludes royalties, is not guaranteed and concerns programmes that remain pre-IND rather than approved treatments.
Field | Content |
Licensing Company | Pfizer |
Partner Company | Starna Therapeutics |
Announcement Date | 18 November 2026 |
Agreement Type | Exclusive licensing agreement |
Technology | In vivo chimeric antigen receptor T-cell (CAR-T) therapy |
Licensed Programmes | Three preclinical in vivo CAR-T programmes |
Primary Therapeutic Focus | Autoimmune diseases |
Additional Technology Rights | Immunology and oncology |
Development Stage | Preclinical and pre-IND |
Geographic Rights | Principal licensed territories outside Greater China with options to expand rights |
Development Responsibilities | Pfizer to lead clinical development outside Greater China |
Upfront Payment | $330 million |
Potential Milestone Payments | Up to $2.3 billion in development and commercial milestones |
Maximum Potential Deal Value | Approximately $2.63 billion excluding royalties |
Additional Consideration | Royalties on applicable future commercial sales |
Deal Significance | Expands Pfizer's in vivo cell therapy capabilities; milestone payments are contingent and no licensed programme is approved |
Primary Source | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-starna |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


コメント